GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 11:28:39 2024-06-25 am EDT 5-day change 1st Jan Change
1,593 GBX -0.95% Intraday chart for GSK plc -1.05% +9.98%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer CI
European Equities Close Higher on Monday; EU Probes Apple for Breach of Digital Competition Law MT
Key week for monetary policy Our Logo
GSK Says Omjjara Approved in Japan to Treat Myelofibrosis MT
GSK's Application for Endometrial Cancer Treatment Expansion Accepted for Review in Europe MT
AlphaValue/Baader Europe Upgrades GSK to Buy from Add, Lifts PT MT
ANALYST RECOMMENDATIONS : Accenture, Walgreens Boots Alliance, Ge Vernova, Pepsico, Britvic... Our Logo
GSK applies to the EMA for an expanded indication for Jemperli CF
GSK: Japan approves Omjjara for myelofibrosis CF
GSK hails Omjjara approval in Japan; Jemperli review in EU AN
GSK's Endometrial Cancer Treatment Accepted for Review in EU MT
Prudential announces buyback; Frasers and THG in deal AN
GSK Obtains Japan's Approval for Myelofibrosis Treatment Omjjara MT
GSK's Request to Expand Cancer Drug Jemperli Use to Be Reviewed by EU DJ
Gsk PLC - Omjjara Approved In Japan For Myelofibrosis RE
Gsk PLC - EMA Validates Jemperli Marketing Authorisation RE
GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis CI
Jemperli(dostarlimab) plus chemotherapy Application Accepted for Review by the European Medicines Agency to Expand Use to All Patients with Primary Advanced or Recurrent Endometrial Cancer CI
GSK : Berenberg renews its buy recommendation CF
GSK : Deutsche Bank remains its Buy rating ZD
GSK : UBS gives a Buy rating ZD
GSK : JP Morgan remains a Sell rating ZD
GSK : Goldman Sachs remains Neutral ZD
GSK : Jefferies reiterates its Buy rating ZD
GSK: Phase III study with iTeos begins CF
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.08 GBP
Average target price
20.36 GBP
Spread / Average Target
+26.61%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies